Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put TECH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 39% growth a year, above the roughly 8% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 0% a day.
View RiskTECH's revenue growth must continue to justify its current valuation. Revenue grew 1% year over year, and the last quarter beat expectations. It trades at 39× P/E versus a peer median of 34×. The market is pricing in more growth than forecast, indicating expectations look full. If TECH cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 39% below where it trades. Our read remains intact.
Trailing returns as of 2026-09-04. TECH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering TECH (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for TECH in the last 4 months.
Continue this research
Compare TECH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TECH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put TECH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve revenue growth
Earnings and revenue growth support management's growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $72.43
The last 12 months of price, then the range of analyst 12-month targets from today’s $72.43.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Achieve revenue growth
In-line earnings and revenue beat support growth objectives.

Advances: Achieve revenue growth
Expansion supports revenue growth through innovative product offerings.

Acquisition enhances growth potential and market position.
Advances: Achieve revenue growth
Acquisition enhances growth potential and market position.
Acquisition enhances growth potential and market position.
Acquisition enhances growth potential and market position.
New collaboration enhances growth potential through innovative products.